Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
复制标题
DOI：
10.1200/jco.2006.06.2497
复制
发表时间：
2006-09-20
影响因子：
45.3
通讯作者：
Smith, Matthew R.
中科院分区：
文献类型：
--
作者：
Keating, Nancy L.;O'Malley, A. James;Smith, Matthew R.
PurposeAndrogen deprivation therapy with a gonadotropin-releasing hormone (GnRH) agonist is associated with increased fat mass and insulin resistance in men with prostate cancer, but the risk of obesity-related disease during treatment has not been well studied. We assessed whether androgen deprivation therapy is associated with an increased incidence of diabetes and cardiovascular disease.Patients and MethodsObservational study of a population-based cohort of 73,196 fee-for-service Medicare enrollees age 66 years or older who were diagnosed with locoregional prostate cancer during 1992 to 1999 and observed through 2001. We used Cox proportional hazards models to assess whether treatment with GnRH agonists or orchiectomy was associated with diabetes, coronary heart disease, myocardial infarction, and sudden cardiac death.ResultsMore than one third of men received a GnRH agonist during follow-up. GnRH agonist use was associated with increased risk of incident diabetes (adjusted hazard ratio [HRI, 1.44; P
